Clinical trials: Chronic Hepatitis C - Genotype 3
Hepatitis C
Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
This study will evaluate the safety, tolerability, and antiviral efficacy of GS-7977 with ribavirin (RBV) in participants with genotype 2 or 3 hepatitis C virus (HCV) infection.
- Trial name
- NCT01682720
- Testing
- SOF, RBV
- Where
- 77 sites in Austria, Estonia and 8 more
- Volunteers
- 421 people
- Sponsor
- Gilead Sciences
Hepatitis C
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
The purpose of this study is to determine whether a regimen consisting of daclatasvir and asunaprevir is effective in treatment-naive patients with chronic hepatitis genotype 1b infection.
- Trial name
- NCT02496078
- Testing
- Daclatasvir, Asunaprevir
- Where
- 29 sites in China, Russia and 1 more
- Volunteers
- 207 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)
This study involves treatment with boceprevir or placebo in combination with PegIntron (PEG) + Ribavirin (RBV) (weight-based dosing [WBD]) in previously untreated adult participants with chronic hepatitis C (CHC) genotype 1.
- Trial name
- SPRINT-2 (NCT00705432)
- Testing
- Peginterferon alfa-2b (PEG), Ribavirin (RBV), Boceprevir
- Volunteers
- 1,472 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)
This is an Australian, open-label, multicenter, randomized, double-blind clinical trial designed to assess the efficacy of combination therapy with pegylated interferon alfa-2b and ribavirin for 48 weeks versus 24 weeks in the…
- Trial name
- NCT00255034
- Testing
- Peginterferon alfa-2b, Ribavirin
- Volunteers
- 146 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6
The interferon- and ribavirin- (RBV) free combination regimen of glecaprevir plus pibrentasvir (GLE/PIB) for the treatment of genotypes 1 to 6 of chronic hepatitis C (CHC) viral infection has been shown to be safe and effective…
- Trial name
- NCT03303599
- Where
- 156 sites in Austria, Belgium and 7 more
- Volunteers
- 2,118 people
- Sponsor
- AbbVie
Chronic Hepatitis C
Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
The purpose of the study is to determine whether therapy with the combination of PSI-7977 and daclatasvir (BMS-790052) with or without ribavirin is effective in treating hepatitis C virus (HCV) infection when given for 12 or 24…
- Trial name
- NCT01359644
- Testing
- PSI-7977, Daclatasvir, Ribavirin
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 350 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
This randomized, double-blind, placebo-controlled, 3-part study will assess the safety, tolerability, and pharmacokinetics of orally administered ALS-002200 in healthy volunteers (HV) and subjects with chronic hepatitis C (CHC)…
- Trial name
- NCT01590407
- Testing
- ALS-002200
- Where
- 4 sites in France, Moldova and 1 more
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Hepatitis C Virus Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection
This study will evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) plus ribavirin (RBV) in treatment-naive adults with chronic genotype 3 hepatitis C virus…
- Trial name
- NCT02413593
- Testing
- LDV/SOF, RBV
- Where
- 15 sites in Canada
- Volunteers
- 111 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C Virus Infection, Genotype 1
A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C
The general aim of this study is to determine if 3 MIU of IFN-α5 in monotherapy, and 1,5 MIU of IFN-α5 combined with 1,5 MIU of IFN- α2b, are safe dose levels as well as to investigate the antiviral efficacy and pharmacodynamics…
- Conditions
- Chronic Hepatitis C Virus Infection, Genotype 1, Treatment-Experienced Patients, Relapses
- Trial name
- NCT01121731
- Testing
- Interferon α-5, Interferon-α5 plus Interferon-α 2b, Interferon α-2b (INTRON® A)
- Where
- 15 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Digna Biotech S.L.
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
The primary objective of this study is to evaluate the antiviral efficacy, safety, and tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and ribavirin (RBV) in participants with chronic…
- Trial name
- NCT02822794
- Testing
- SOF/VEL, RBV
- Where
- 18 sites in Japan
- Volunteers
- 117 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus Infection
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
The purpose of the study is to investigate the efficacy and safety of 12 weeks of simeprevir (150 mg qd) in combination with sofosbuvir (400 mg qd) in chronic hepatitis C virus (HCV) genotype 1 infected men and women with…
- Trial name
- NCT02114151
- Testing
- Simeprevir, Sofosbuvir
- Where
- 34 sites in United States, Canada
- Volunteers
- 103 people
- Sponsor
- Janssen Infectious Diseases BVBA
Chronic Hepatitis C
Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection
The purpose of this study is to evaluate the antiviral efficacy, safety, tolerability of combination therapy with sofosbuvir (SOF) containing regimens for the treatment of chronic hepatitis C virus (HCV) infection.
- Trial name
- NCT01826981
- Testing
- LDV/SOF, SOF, RBV
- Where
- 2 sites in New Zealand
- Volunteers
- 359 people
- Sponsor
- Gilead Sciences
Hepatitis C, Human Immunodeficiency Virus
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) plus ribavirin (RBV) in adults with chronic genotypes 1, 2, and 3 HCV infection who are coinfected with HIV-1.
- Trial name
- NCT01667731
- Testing
- SOF, RBV
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 224 people
- Sponsor
- Gilead Sciences
Hepatitis C
Phase 3 Study of Sofosbuvir and Ribavirin
This study was to assess the safety and efficacy of sofosbuvir (GS-7977; PSI-7977) in combination with ribavirin (RBV) administered for 12 weeks compared with pegylated interferon (PEG)/RBV administered for 24 weeks in…
- Trial name
- FISSION (NCT01497366)
- Testing
- Sofosbuvir, PEG, RBV
- Where
- 97 sites in United States, Australia and 6 more
- Volunteers
- 527 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
The purpose of this study is to assess efficacy, as determined by the proportion of subjects with Sustained Virologic Response at Post-Treatment Week 12 (SVR12), defined as Hepatitis C virus (HCV) Ribonucleic acid (RNA) < Limit…
- Trial name
- Hallmark QUAD (NCT01573351)
- Testing
- Asunaprevir, Daclatasvir, Peg-interferon Alfa-2a
- Where
- 79 sites in United States, Argentina and 13 more
- Volunteers
- 398 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6
The Chinese patients with chronic hepatitis C have a different genetic background, which had been demonstrated to significantly influence their responses to pegylated interferon and ribavirin.
- Trial name
- NCT01433887
- Testing
- 48-weeks course, Ribavirin, Peginterferon alfa2a
- Where
- 3 sites in China
- Volunteers
- 535 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis C, Chronic
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
The primary purpose of this study is to compare the efficacy of two boceprevir (BOC)-containing therapeutic regimens in the treatment of naïve participants with chronic hepatitis C virus (HCV) genotype 1 who have the IL28B CC…
- Trial name
- NCT01544920
- Testing
- peg-Interferon alfa-2a, Ribavirin, Boceprevir
- Volunteers
- 737 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus
Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection
To identify a shorter duration of antiviral therapy (12 or 16 weeks) for the combination of daclatasvir with pegylated interferon alfa-2a and ribavirin.
- Trial name
- NCT01257204
- Testing
- Daclatasvir, Pegylated interferon alfa-2a, Ribavirin
- Where
- 26 sites in United States, Australia and 4 more
- Volunteers
- 196 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C Infection
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
The purpose of this study is to assess the safety, tolerability, and efficacy of Sofosbuvir containing regimens in treatment-naive or treatment-experienced patients with HCV genotype 3 infection.
- Trial name
- NCT02576314
- Testing
- sofosbuvir and daclatasvir, ledipasvir/sofosbuvir
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Humanity and Health Research Centre
Chronic Hepatitis C
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients
This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa 2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination…
- Trial name
- NCT00402428
- Testing
- albumin interferon alfa-2b, peginterferon alfa-2a, Ribavirin
- Where
- 165 sites in United States, Australia and 13 more
- Volunteers
- 1,331 people
- Sponsor
- Human Genome Sciences Inc.